PMID- 25131093
OWN - NLM
STAT- MEDLINE
DCOM- 20150923
LR  - 20221207
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 46
IP  - 6
DP  - 2014 Jul-Aug
TI  - Xenograft of microencapsulated Sertoli cells for the cell therapy of type 2 
      diabetes mellitus in spontaneously diabetic nonhuman primates: preliminary data.
PG  - 1999-2001
LID - S0041-1345(14)00492-8 [pii]
LID - 10.1016/j.transproceed.2014.06.053 [doi]
AB  - Insulin resistance in type 2 diabetes mellitus (T2DM) may be due to a chronic 
      inflammation of the visceral adipose tissue (VAT) leading to local and systemic 
      increases in proinflammatory cytokines. Microencapsulated porcine Sertoli cells 
      (MC-pSC), by provision of immunomodulatory and trophic factors, have been 
      successfully used to reduce such inflammation in rodent animal models of type 1 
      diabetes with no complications or deleterious side effects. Herein, we have begun 
      to investigate this novel and safe therapeutic approach in the spontaneously 
      obese nonhuman primate with spontaneous, insulin-dependent T2DM. After MC-pSC 
      intraperitoneal injection we have evaluated, throughout a 6-month follow-up 
      period, daily ad libitum fed glucose levels, daily exogenous insulin 
      supplementation, biweekly body weight measurements, periodic fasting blood 
      glucose concentrations, glycated hemoglobin (HbA1c) levels, glucose tolerance 
      tests (GTT), and fluorescence-activated cell sorting cytometry (FACS) assessment 
      of peripheral blood mononuclear cells. Very preliminarily, we have observed a 
      slight reduction in fasting (FPG) and mean nonfasting (NF) plasma glucose levels. 
      We found minimal changes, only in 1 animal, in daily exogenous insulin 
      requirements and HbA1c levels. Flow cytometric analysis was associated with 
      decrease in CD8(+) cells only in 1 recipient with a reduction in mean regulatory 
      T Cells (Treg), whereas interestingly, decrease of B lymphocytes was observed in 
      both animals. These results may suggest that this novel MC-SC-based 
      transplantation protocol might possibly impact the metabolic status of T2DM in 
      higher mammals that are close to humans.
CI  - Copyright (c) 2014. Published by Elsevier Inc.
FAU - Luca, G
AU  - Luca G
AD  - Department of Experimental Medicine and Biochemical Sciences, University of 
      Perugia, Perugia, Italy.
FAU - Cameron, D F
AU  - Cameron DF
AD  - Department of Internal Medicine, University of South Florida, Tampa, FL.
FAU - Arato, I
AU  - Arato I
AD  - Department of Experimental Medicine and Biochemical Sciences, University of 
      Perugia, Perugia, Italy.
FAU - Mancuso, F
AU  - Mancuso F
AD  - Department of Experimental Medicine and Biochemical Sciences, University of 
      Perugia, Perugia, Italy.
FAU - Linden, E H
AU  - Linden EH
AD  - Department of Internal Medicine, University of South Florida, Tampa, FL.
FAU - Calvitti, M
AU  - Calvitti M
AD  - Department of Experimental Medicine and Biochemical Sciences, University of 
      Perugia, Perugia, Italy.
FAU - Falabella, G
AU  - Falabella G
AD  - Department of Experimental Medicine and Biochemical Sciences, University of 
      Perugia, Perugia, Italy.
FAU - Szekeres, K
AU  - Szekeres K
AD  - Department of Internal Medicine, University of South Florida, Tampa, FL.
FAU - Bodo, M
AU  - Bodo M
AD  - Department of Experimental Medicine and Biochemical Sciences, University of 
      Perugia, Perugia, Italy.
FAU - Ricci, G
AU  - Ricci G
AD  - Department of Internal Medicine, University of Perugia, Perugia, Italy.
FAU - Hansen, B C
AU  - Hansen BC
AD  - Department of Internal Medicine, University of South Florida, Tampa, FL.
FAU - Calafiore, R
AU  - Calafiore R
AD  - Department of Internal Medicine, University of Perugia, Perugia, Italy. 
      Electronic address: riccardo.calafiore@unipg.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Animals
MH  - Cell- and Tissue-Based Therapy/*methods
MH  - Diabetes Mellitus, Type 2/blood/etiology/*therapy
MH  - Drug Compounding
MH  - Glycated Hemoglobin/metabolism
MH  - Hypoglycemic Agents/therapeutic use
MH  - Injections, Intraperitoneal
MH  - Insulin/therapeutic use
MH  - Insulin Resistance/physiology
MH  - Macaca mulatta
MH  - Male
MH  - Obesity/complications
MH  - Sertoli Cells/*transplantation
MH  - Swine
MH  - *Transplantation, Heterologous
EDAT- 2014/08/19 06:00
MHDA- 2015/09/24 06:00
CRDT- 2014/08/19 06:00
PHST- 2014/08/19 06:00 [entrez]
PHST- 2014/08/19 06:00 [pubmed]
PHST- 2015/09/24 06:00 [medline]
AID - S0041-1345(14)00492-8 [pii]
AID - 10.1016/j.transproceed.2014.06.053 [doi]
PST - ppublish
SO  - Transplant Proc. 2014 Jul-Aug;46(6):1999-2001. doi: 
      10.1016/j.transproceed.2014.06.053.